Last edition
News about "BioNTech"
BioNTech and OncoC4 Report Survival Benefit with Gotistobart in Squamous NSCLC
BioNTech and OncoC4 report updated phase 3 data showing gotistobart improved median Overall Survival (OS) to 18.5 months versus 10 months with chemotherapy in previously treated squamous NSCLC.
BioNTech | 14/09/2026 | By News Bureau | 155
EU Approves Pfizer-BioNTech XFG-Adapted COVID-19 Vaccine
The European Commission (EC) has approved Pfizer-BioNTech's XFG-adapted COVID-19 vaccine, with more than 5 billion vaccine doses distributed worldwide.
BioNTech | 30/07/2026 | By News Bureau | 113
The collaboration between Boehringer Ingelheim and BioNTech will evaluate a dual immuno-oncology approach in extensive-stage small cell lung cancer, aiming to improve outcomes in a disease with limited treatment options.
BioNTech | 11/04/2026 | By News Bureau | 174
BioNTech files patent lawsuit against Moderna over COVID-19 vaccine technology
German biotechnology firm BioNTech has filed a patent infringement lawsuit against U.S.-based vaccine maker Moderna in a federal court in Delaware. The case centers on Moderna’s updated COVID-19 vaccine, mNEXSPIKE, which BioNTech claims uses technology protected under its patents.
BioNTech | 20/02/2026 | By Darshana | 224
Pfizer Cuts Majority of Its BioNTech Stake in Strategic Realignment
After the sale, Pfizer now holds around 1.66 million American Depositary Shares, valued at roughly USD 163 million as of late September 2025.
BioNTech | 14/11/2025 | By Darshana | 317
BioNTech and Duality Biologics reach major breakthrough in breast cancer trial
BioNTech and Duality Biologics have announced a significant advance in cancer drug development with the successful outcome of a Phase III trial for their investigational therapy BNT323, also known as trastuzumab pamirtecan.
BioNTech | 06/09/2025 | By Darshana | 287
Pfizer and BioNTech's Updated COVID-19 Vaccine Secures EMA Nod, Awaits Final EU Approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Pfizer- BioNTech's LP.8.1-adapted monovalent COVID-19 vaccine in the European Union.
BioNTech | 28/07/2025 | By Dineshwori | 313
BioNTech | 14/03/2023 | By Sudeep Soparkar | 915
BioNTech to invest $43 M in German facility for mRNA vaccine
With the facility, BioNTech is seeking more control over the supply chain
BioNTech | 04/02/2023 | By Sudeep Soparkar | 644
BioNTech | 15/11/2022 | By Sudeep Soparkar | 1060
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy